Back to search
FDAFDA · Food and drugs·Recall number D-0732-2016

Capecitabine tablets USP 500 mg, Cytotoxic Agent, Rx Only, 120 tablets per bottle, Manufactured in Czech Republic by: Teva Czech Industries sro, Czech Republic, Manufactured for: Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-7474-89

Published March 9, 2016 · Recall initiated: December 21, 2015

Summary

FDA records drug Class II recall D-0732-2016, published March 9, 2016 and initiated December 21, 2015. Recalling firm: Teva North America; Status: Terminated; Reported quantity: 1,895 bottles; Lot: Lot # 3A404012V, Exp. 4/2016. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: low test results at the 18 month time-point

What to do

Voluntary: Firm initiated · Letter

Get an email if CAPECITABINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CAPECITABINE
Manufacturer
Teva North America
Distributor
Nationwide
Lot
Lot # 3A404012V, Exp. 4/2016
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Capecitabine tablets USP 500 mg, Cytotoxic Agent, Rx Only, 120 tablets per bottle, Manufactured in Czech Republic by: Teva Czech Industries sro, Czech Republic, Manufactured for: Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-7474-89 recalled?

Yes. FDA published recall D-0732-2016 on March 9, 2016. Reported hazard: Failed Dissolution Specifications: low test results at the 18 month time-point

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CAPECITABINE.